X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indoco Remedies Fact Sheet, Indoco Remedies Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indoco Remedies Fact Sheet   (INDOCO)

Here is the latest financial fact sheet of Indoco Remedies. For more details, see the Indoco Remedies quarterly results and Indoco Remedies share price and chart. For a sector overview, read our pharmaceuticals sector report.

INDOCO REMEDIES Price History

Price Rs 293.4
Mkt Cap Rs m 27,040
Vol '000 32.4
P/E X 34.9
P/CF X 19.3
EPS (TTM) Rs 8.4
% ch % -0.7
No. of shares m 92.18
% ch week % 9.1
% ch 1-mth % 15.8
% ch 12-mth % 5.0
52 week H/L Rs 314.0/179.0
(As on Nov 24, 2017 02:47:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

INDOCO REMEDIES Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
INDOCO REMEDIES EQUITY SHARE DATA
High Rs83162378412360 
Low Rs5155131263249 
Sales per share (Unadj.) Rs68.579.593.0109.4119.0 
Earnings per share (Unadj.) Rs4.66.39.08.98.4 
Diluted earnings per shareRs4.66.39.08.98.4 
Cash flow per share (Unadj.) Rs7.29.614.115.515.2 
Dividends per share (Unadj.) Rs1.101.401.601.601.60 
Adj. dividends per shareRs1.101.401.601.601.60 
Dividend yield (eoy) %1.61.30.60.50.5 
Book value per share (Unadj.) Rs44.949.657.362.670.7 
Adj. book value per shareRs44.949.657.362.570.7 
Shares outstanding (eoy) m92.1592.1592.1592.1592.15 
Bonus/Rights/Conversions  FV2, B1:2---- 
Price / Sales ratio x1.01.42.73.12.6 
Avg P/E ratio x14.517.228.337.936.4 
P/CF ratio (eoy) x9.311.218.021.820.0 
Price / Book Value ratio x1.52.24.45.44.3 
Dividend payout %23.722.217.818.019.1 
Avg Mkt Cap Rs m6,1749,98923,43831,08728,083 
No. of employees `000NANANA5.76.0 
Total wages/salary Rs m1,0791,2951,4001,8192,167 
Avg. sales/employee Rs ThNMNMNM1,762.41,817.0 
Avg. wages/employee Rs ThNMNMNM318.0359.0 
Avg. net profit/employee Rs ThNMNMNM143.3127.7 
INDOCO REMEDIES INCOME DATA
Net Sales Rs m6,3087,3268,57010,08110,968 
Other income Rs m1518171640 
Total revenues Rs m6,3237,3448,58710,09711,007 
Gross profit Rs m9261,2041,6551,7041,565 
Depreciation Rs m237309471607633 
Interest Rs m21918910612462 
Profit before tax Rs m4867231,096989909 
Minority Interest Rs m0-1000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m58143267170139 
Profit after tax Rs m427580828819771 
Gross profit margin %14.716.419.316.914.3 
Effective tax rate %11.919.824.417.215.3 
Net profit margin %6.87.99.78.17.0 
INDOCO REMEDIES BALANCE SHEET DATA
Current assets Rs m2,7553,0463,8904,6465,725 
Current liabilities Rs m1,9932,0222,9263,6415,454 
Net working cap to sales %12.114.011.310.02.5 
Current ratio x1.41.51.31.31.0 
Inventory Days Days5455646062 
Debtors Days Days7469666872 
Net fixed assets Rs m3,5923,6944,0224,2965,307 
Share capital Rs m184184184184184 
"Free" reserves Rs m3,9504,3805,0935,5816,331 
Net worth Rs m4,1424,5725,2775,7656,516 
Long term debt Rs m2741381293791,323 
Total assets Rs m6,9197,2948,2039,40611,970 
Interest coverage x3.24.811.49.015.6 
Debt to equity ratio x0.1000.10.2 
Sales to assets ratio x0.91.01.01.10.9 
Return on assets %9.310.511.410.07.0 
Return on equity %10.312.715.714.211.8 
Return on capital %15.919.422.218.112.4 
Exports to sales %33.533.936.240.10 
Imports to sales %5.45.47.57.70 
Exports (fob) Rs m2,1162,4803,1014,0440 
Imports (cif) Rs m3433966437730 
Fx inflow Rs m2,1162,4803,1014,0444,507 
Fx outflow Rs m4455498191,0171,141 
Net fx Rs m1,6711,9312,2823,0273,366 
INDOCO REMEDIES CASH FLOW
From Operations Rs m 687 988 1,090 1,122 886 
From Investments Rs m -426 -410 -884 -1,107 -1,706 
From Financial Activity Rs m -244 -590 -199 -16 1,316 
Net Cashflow Rs m 17 -12 7 -1 497 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 59.2%
Foreign collaborators 0.0%
Indian inst/Mut Fund 12.5%
FIIs 6.0%
ADR/GDR 0.0%
Free float 22.4%
Shareholders 12,805
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 166, Indoco House, CST Road, kalina, Santacruz (E), Mumbai - 400 098
E-MAIL sunil.joshi@indoco.com WEB www.indoco.com
TELEPHONE (022) 2654 1851 FAX (022) 2652 3067
SECTOR MISCELLANEOUS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Patkar & Pendse
CHM: Suresh G. Kare (MD) COMP SEC: Sunil D. Joshi YEAR OF INC: 1945 BSE CODE: 532612 FV (Rs): 2 DIV YIELD (%): 0.5

More Miscellaneous Company Fact Sheets:   MERCK LTD  INDRAPRASTHA MEDICAL  DISHMAN PHARMA  PFIZER  GSK PHARMA  

Compare INDOCO REMEDIES With:   MERCK LTD  INDRAPRASTHA MEDICAL  DISHMAN PHARMA  PFIZER  GSK PHARMA  

Compare INDOCO REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; IT Stocks Top Gainers(01:30 pm)

After opening the day marginally higher, share markets in India continued the momentum and are presently trading in green.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

When the Sherlock Holmes in Me Follows Super Investors...(The 5 Minute Wrapup)

Nov 11, 2017

This Super Investor has knack of spotting megatrends in India.

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS